Form 4: UTHR CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, executed pre-arranged stock option exercises and subsequent sales of common stock on September 25 and 26, 2025.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving common stock.
• On September 25, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• Following the exercise on September 25, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $429.0678 to $431.9026 per share.
• On September 26, 2025, Rothblatt again exercised 4,000 stock options at an exercise price of $120.26 per share.
• Following the exercise on September 26, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $426.86 to $428.677 per share.
• All reported exercises and sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of common stock.
• Indirect beneficial ownership includes 166 shares by spouse, 324,518 shares by a family trust where the Reporting Person shares investment power, 258,117 shares by a family trust where the spouse is sole trustee, 45,596 shares by a family trust where the spouse shares investment power, and 15,962 shares by a family trust where the Reporting Person is sole trustee.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While insider selling can sometimes be viewed negatively, the fact that it's a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized from the option exercises reflects positively on the company's stock performance and the value created for shareholders over time.

Positives

• The exercise of stock options at a significantly lower price ($120.26) compared to the sale prices (ranging from $426.86 to $431.9026) indicates substantial profitability for the insider, reflecting a strong appreciation in the company's stock value over time.
• The transactions were executed under a pre-arranged 10b5-1 trading plan, which demonstrates a structured and compliant approach to insider trading, reducing concerns about opportunistic selling.

Negatives

• The sale of a significant number of shares by a key executive, even under a pre-arranged plan, could be perceived by some investors as a lack of confidence in the company's near-term growth prospects, although this is often a routine liquidity event.

Risks

• Market volatility could impact the prices at which future sales under the 10b5-1 plan are executed, potentially affecting the total proceeds received by the reporting person.
• The expiration of a tranche of 294,000 stock options on March 15, 2026, creates a deadline for their exercise, which could lead to further sales activity as the date approaches.

Future Outlook

The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025, indicating potential for further similar transactions.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence in publicly traded companies. These plans allow insiders to sell shares over a predetermined period to avoid accusations of trading on material non-public information. The profitability of these option exercises reflects the general positive performance of the biotechnology and pharmaceutical sector, where United Therapeutics operates, over the period since the options were granted.

Comparison to Industry Standards

• NA

Related Party Transactions

• The reporting person holds indirect beneficial ownership through various family trusts, including those where the reporting person or their spouse share investment power or are beneficiaries/trustees. These indirect holdings represent related party interests.

Stakeholder Impact

• Shareholders: May view the insider selling with mixed reactions; some may see it as a routine liquidity event for the executive, while others might interpret it as a signal, despite the 10b5-1 plan.
• Employees: No direct impact mentioned, but executive transactions can sometimes influence morale or perception of company stability.
• Investment Professionals: Will likely view these transactions as routine under a 10b5-1 plan, focusing on the underlying company performance rather than these specific sales as a primary indicator.

Next Steps

• The pre-arranged 10b5-1 trading plan is expected to continue, potentially leading to further exercises and sales of the remaining 234,000 stock options before their expiration on March 15, 2026, or the plan's termination on December 31, 2025.

Key Dates

Recommendation

The filing details routine insider transactions (option exercises and sales) executed under a pre-arranged 10b5-1 plan. While the sales are significant in volume, their pre-planned nature reduces their immediate signaling impact on the company's future prospects. The transactions reflect the executive realizing value from long-held options, which is a common and expected event. This filing alone does not provide new fundamental information about United Therapeutics' business operations, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than these specific insider sales.

Keywords

United Therapeutics, UTHR, Martine A. Rothblatt, SEC Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, Beneficial Ownership